Novo Nordisk, through an unrestricted educational grant as part of our Changing Diabetes® Leadership Initiative, is honored to support the AFMRD Frontline: Diabetes program. For the past 4 years, this program has offered family medicine residents an opportunity to learn the latest information about diabetes care. Since the majority of people living with type 2 diabetes are cared for by primary care physicians, this knowledge is crucial in helping you work with your patients to achieve their treatment goals.

Committed to Changing Diabetes, we want all people with diabetes to achieve good glycemic control, and we are passionate about providing support in battling this devastating disease. Novo Nordisk is the only company with a comprehensive portfolio of insulin analogs and we’ve designed our advanced insulin delivery systems to be accurate and convenient for patients to use.

Novo Nordisk is different from other pharmaceutical companies; we consider ourselves a healthcare company. We are owned by the Novo Nordisk Foundation, which is dedicated to making scientific, humanitarian and social progress. Additionally, to improve diabetes care and increase access in developing countries, we established the World Diabetes Foundation, donating approximately $100 million. Finally, our organization contains the Hagedorn Research Institute, which is supported by grants from the National Institutes of Health and Juvenile Diabetes Research Foundation, as an independent basic research site seeking a cure for diabetes, and the Steno Diabetes Center, a World Health Organization Collaborating diabetes hospital.

Novo Nordisk is committed to pursuing its business in a responsible manner defined by our Triple Bottom Line approach to doing business - creating a sustainable business that is financially viable while being socially responsible and environmentally sound.

We’re pleased to support AFMRD and Frontline: Diabetes and hope you share our excitement in this important educational innovation. Together we can change diabetes by ensuring that those living with this disease receive the most up-to-date and highest quality care.

Jerzy Gruhn
President, Novo Nordisk Inc.